个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述

Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase Ⅲ studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use o...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999997/
https://www.ncbi.nlm.nih.gov/pubmed/22104223
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.11.08
Descripción
Sumario:Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase Ⅲ studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC..

Ejemplares similares